Immunotherapy in Inflammatory Bowel Disease

Medical Clinics of North America

Volumn 96, Issue 3, 2012, Pages 525-544

  Ahluwalia, Jatinder P ^a,b  

^a Gastroenterology Clinic of Acadiana   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Anti 4 integrin therapy; Anti tumor necrosis factor ; Biologics; Certolizumab; Crohn disease; Infliximab; Natalizumab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ADRENALIN; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BRIAKINUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CERTOLIZUMAB PEGOL; CHIMERIC MONOCLONAL ANTI HUMAN CD40 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PARACETAMOL; PLACEBO; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB;

ALLERGIC REACTION; ARTHRALGIA; ASPERGILLOSIS; BIOLOGICAL THERAPY; BURNING SENSATION; CANDIDIASIS; COLON RESECTION; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSPNEA; ENTERITIS; ERYTHEMA; FISTULA; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; LISTERIOSIS; LYMPHOCYTE; LYMPHOMA; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MOLECULE; MYALGIA; PAIN; PATHOGENESIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SEPSIS; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; INTESTINAL FISTULA; INTESTINAL MUCOSA; NEOPLASMS; OPPORTUNISTIC INFECTIONS; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84862325248     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.009     Document Type: Review

References (95)

1. Korzenik J.R., Podolsky D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006, 5:197-209.
2. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
3. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
4. Loftus C.G., Loftus E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmstead County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
5. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
6. Cho J., Brant S.R. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011, 140:1704-1712.
7. Tsironi E., Feakins R.M., Probert C.S., et al. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is following in Bangladeshis and East London, United Kingdom. Am J Gastroenterol 2004, 99:1749-1755.
8. Halme L., Paavola-Sakki P., Turunen U., et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006, 12:3668-3672.
9. Thia K.T., Loftus E.V., Sandborn W.J., et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008, 103:3167-3182.
10. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Ann Rev Immunol 2010, 28:573-621.
11. Faubion W.A., Loftus E., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
12. Ho G.T., Chiam P., Drummond H., et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006, 24:319-330.
13. Munkholm P., Langholz E., Davidsen M., et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
14. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
15. Murch S.H., Lamkin V.A., Savage M.O., et al. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991, 32:913-917.
16. Breese E.J., Michie C.A., Nicholls S.W., et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106:1455-1466.
17. MacDonald T.T., Hutchings P., Choy M.Y., et al. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990, 81:301-305.
18. Braegger C.P., Nicholls S., Murch S.H., et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339:89-91.
19. Nielsen O.H., Gionchetti P., Ainsworth M., et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999, 94:2923-2928.
20. Saiki T., Mitsuyama K., Toyonaga A., et al. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998, 33:616-622.
21. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
22. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359:1541-1549.
23. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
24. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
25. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
26. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
27. Sandborn W.J., Schreiber S., Feagan B.G., et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011, 9:670-678.
28. Baumgart D.C., Targan S.R., Dignass A.U., et al. Prospective randomized open-labile multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010, 16:620-629.
29. Plevy S., Salzberg B., Van Assche G., et al. A phase I study of visilizumab, a humanized anti-CD 3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007, 133:1414-1422.
30. Kasran A., Boon L., Wortel C.H., et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005, 22:111-122.
31. Van Assche G., Sandborn W.J., Feagan B.G., et al. Daclizumab, a humanized monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, and dose ranging trial. Gut 2006, 55:1568-1574.
32. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004, 126:989-996.
33. Elliott M., Benson J., Blank M., et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009, 1182:97-110.
34. Mannon P.J., Fuss I.J., Elson C.O., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
35. Toedter G.P., Blank M., Lang Y., et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009, 104:2768-2773.
36. Sandborn W.J., Feagan B.G., Fedorak R.N., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
37. Ghosh S., Gordin E., Gordon F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
38. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
39. Feagan B.G., Greenberg F.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
40. Van Dullemen H.M., van Deventer S.J., Hommes D.W., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
41. Reinisch W., Wang Y., Oddens B.J., et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012, 35:568-576.
42. Schnitzler F., Fidder H., Ferrante M., et al. Long term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-center cohort. Gut 2009, 58:492-500.
43. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
44. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
45. Sands B.E., Blank M.A., Patel K., et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004, 2:912-920.
46. Guidi L., Pugliese D., Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol 2011, 4:163-172.
47. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
48. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
49. Kamm M.A., Hanauer S.B., Panaccione R., et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011, 34:306-317.
50. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
51. Ma C., Panaccione R., Heitman S.J., et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009, 30:977-986.
52. Lichtiger S., Binion D.G., Wolf D.C., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
53. Afif W., Leighton J.A., Hanauer S.B., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009, 15:1302-1307.
54. Gies N., Krocker K.I., Wong K., et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-center cohort. Aliment Pharmacol Ther 2010, 32:522-528.
55. Oussalah A., Laclotte C., Chevaux J.B., et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-center experience. Aliment Pharmacol Ther 2008, 28:966-972.
56. Peyrin-Biroulet L., Laclotte C., Roblin X., et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007, 13:2328-2332.
57. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
58. Reinisch W., Sandborn W.J., Kumar A., et al. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants [abstract]. J Crohns Colitis 2011, 5:S87.
59. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
60. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
61. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
62. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
63. Ha C., Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Curr Gastroenterol Rep 2010, 12:471-478.
64. Vant M.H. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis 2009, 27:470-475.
65. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
66. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
67. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
68. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
69. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
70. Feagan B.G., Panaccione R., Sandborn W.J., et al. Effects of adalimumab therapy on the incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
71. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
72. Leombruno J.P., Nguyen G.C., Grootendorst P., et al. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf 2011, 20:838-848.
73. Eksteen B., Liaskou E., Adams D.H. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis 2008, 14:1298-1312.
74. Koizumi M., King N., Lobb R., et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992, 103:840-847.
75. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
76. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
77. Update on Tysabri and PML. National Multiple Sclerosis Society Web site. Available at: Published April 11, 2011. Updated January 20, 2012. Accessed March 10, 2012. http://www.nationalmssociety.org/news/news-detail/index.aspx%3Fnid=2308.
78. The TYSABRI TOUCH® Prescribing Program. Tysabri (natalizumab) web site. Available at: Accessed March 15, 2012. http://www.tysabri.com/tysbProject/tysb.portal/_baseurl/threeColLayout/SCSRepository/en_US/tysb/home/treatment-withtysabri/touch-prescribing-program.xml.
79. Targan S.R., Feagan B.G., Fedorak R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
80. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
81. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
82. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
83. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
84. Mayer L., Young Y. Infusion reactions and their management. Gastroenterol Clin North Am 2006, 35:857-866.
85. Hoentjen F., van Bodegraven A.A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009, 15:2067-2073.
86. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
87. Tsiodras S., Samonis G., Boumpas D.T., et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181-194.
88. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
89. Hou J.K., Velayos F., Terrault N., et al. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:925-932.
90. Thai A., Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010, 4:511-522.
91. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685-698.
92. Danese S., Fiorino G., Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- α therapy. Aliment Pharmacol Ther 2011, 34:1-10.
93. Katz L., Gisbert J.P., Manoogian B., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, [Epub ahead of print].
94. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
95. Perrier C., Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011, 3:1341-1352.